目的分析鼻咽癌（NPC）患者鼻出血的危险因素并探讨有效的治疗方法。自2006年3月至2020年2月，共收治鼻咽癌患者351例鼻出血患者，符合纳入标准的患者195例纳入研究。特点和治疗方法，包括加强止血治疗（包括药物、前后鼻孔填塞或进一步手术止血）和CTPI紧急止血方法（包括颈总动脉压迫、气管切开/插管、鼻鼻咽部填塞、介入治疗）治疗），进行了分析。中位总出血量为 100.0 毫升（范围 20-4430 毫升）。 126 名（64.6%）和 69 名（35.4%）患者患有非大量鼻出血和大量鼻出血。大量鼻出血患者的 1 年总生存 (OS) 率为 60.1%，而接受阶梯止血治疗的非大量鼻出血患者的 1 年总生存率为 97.3%。大量鼻出血患者中，接受 CTPI 治疗的 1 年 OS 率为 80.0%，接受升压止血治疗的 1 年 OS 率为 13.3%。ICA 暴露和止血失败是鼻出血鼻出血患者 OS 的不良预后因素。逐步止血治疗可有效控制非大量鼻出血。对于大量鼻出血的鼻咽癌患者，尤其是有 PRNN 和 ICA 暴露的鼻咽癌患者，CTPI 紧急方法可能是一种有效的止血治疗方法。版权所有 © 2024 Elsevier Ltd. 保留所有权利。

To analyze the risk factors and explore effective treatments for epistaxis in nasopharyngeal carcinoma (NPC) patients.From March 2006 to February 2020, 351 epistaxis patients visited our center and 195 patients meeting the inclusion criteria were enrolled in the study. Characteristics and treatments, including step-up hemostatic treatment (including medication, anterior ± posterior nostril packing, or further surgical hemostasis) and the CTPI emergency hemostasis method (including common carotid artery compression, tracheotomy / intubation, packing of nasal and nasopharynx, and interventional treatment), were analyzed.The median total bleeding volume was 100.0 ml (range 20-4430 ml). 126 (64.6 %) and 69 (35.4 %) patients suffered from non-massive epistaxis and massive epistaxis. The 1-year overall survival (OS) rate was 60.1 % for patients with massive epistaxis and 97.3 % for those with non-massive epistaxis treated with step-up hemostatic treatment. Among patients with massive epistaxis, the 1-year OS rate was 80.0 % for those who received CTPI and 13.3 % for those who received step-up hemostatic treatment.ICA exposure and hemostasis failure was adverse prognostic factors for OS in NPC patients with epistaxis. The step-up hemostatic treatment is effective for controlling non-massive epistaxis. The CTPI emergency method might be an effective hemostasis treatment for NPC patients with massive epistaxis, especially those with PRNN and ICA exposure.Copyright © 2024 Elsevier Ltd. All rights reserved.